Lack of Sterility, Lab Controls, Earns Kilitch Healthcare a Form 483

Kilitch Healthcare India received an FDA Form 483 citing lack of sterility, incomplete laboratory records and inadequate laboratory controls, inadequate validation of aseptic processes and unclean and insanitary buildings following an eight-day October inspection of its Mumbai, Maharashtra sterile drug manufacturing facility.
Source: Drug Industry Daily